期刊文献+

新型抗癫痫药醋酸艾司利卡西平 被引量:11

A novel antiepileptic drug-eslicarbazepine acetate
原文传递
导出
摘要 癫痫是一种常见的脑部疾病,由大脑神经元的反复异常放电引起。尽管目前有很多种抗癫痫药物可用,但是约30%的患者存在抗药性或者用药过程中出现了严重的不良反应。醋酸艾司利卡西平是卡马西平的衍生物,由Sunovion Pharmaceuticals Inc.公司研究开发,用于伴有或不伴有继发性全身发作的成人癫痫部分性发作的治疗。它是一种新型电压门控钠通道抑制剂,通过阻断动作电位的传导,以抑制脑神经元的反复异常放电,控制癫痫发作。本文对其作用机制、药动学、药效动力学、临床研究、安全性评价等做一介绍。 Epilepsy is a common neurological disorder caused by recurrent abnormal discharge of neurons in the brain. Although there are many antiepileptic drugs available, 30% of the patients present resistance to those drugs or show serious adverse reactions. Eslicarbazepine acetate (ESL) is one derivative of carbamazepine. It was developed by Sunovion Pharmaceuticals Inc. for treatment of adult epilepsy partial-onset seizures, with or without secondary generalized seizures. ESL is a novel voltage-gated sodium channel inhibitor, it restrains the abnormal discharge by cutting the conduction of nerve action potential, thus controls the epilepsy seizures. This paper summarized the mechanism, pharmacokinetics, pharmacodynamics, clinical trials, and safety assessments of ESL.
出处 《中国新药杂志》 CAS CSCD 北大核心 2014年第21期2461-2464,共4页 Chinese Journal of New Drugs
关键词 醋酸艾司利卡西平 癫痫 电压门控钠通道抑制剂 eslicarbazepine acetate epilepsy voltage-gated sodium channel inhibitor
  • 相关文献

参考文献22

  • 1FDA. Esliearbazepine acetate[ EB/OL]. [ 2013 - 11 - 08 ]. http://www, accessdata, fda. gov/drugsatfda_ docs/label/2013/ 022416 s0001bl, pdf.
  • 2VERROTTI A, LOIACONO G, ROSSI A, et al. Eslicarbazepine acetate: an update on efficacy and safety in epilepsy[J]. Epilep- sy Res, 2014, 108(1) :1 - 10.
  • 3BONIFACIIO M J, SHERIDAN RD, PARADA A, et al. Interac- tion of the novel anticonvulsivant, BIA 2-093, with voltage-gated sodium channels: comparison with carbamazepine[ J]. Epilepsia, 2001, 42 (5) :600 - 608.
  • 4BENES J, PARADA A, FIGUEIREDO AA, et al. Antconvulsi- vant and sodium channel-blocking propeies of novel 10,11-di- hydro-5H-dibenz(b,f) azeplne-5-Carboxamlde devaties[J]. J Med Chem, 1999, 42(14):2582 -2587.
  • 5DOESER A, SOARES DA SILVA effects of eslicarbazepine on persistent of the Na + channel β subunits[ J] (2) :202 -211. P, BECK H, et al. The Na + current and the role Epilepsy Res, 2014, 108.
  • 6PERUCCA E, ELGER C, HALASZ, et al. Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures[ J]. Epilepsy Res, 2011, 96 ( 1 - 2) : 132 - 139.
  • 7LANDMARK C, JOHANNESSEN SI. Modifications of antiepi- leptic drugs for improved tolerability and efficacy [ J ]. Perspect Medicin Chem, 2008, 2:21 -39.
  • 8BIALER M, SOARES DA, SILVA P. Pharmacokinetics and drug interactions of eslicarbazepine acetate[J]. Epilepsia, 2012, 53(6) :935 -946.
  • 9ELGER C, HALASZ P, MAIA J, et al. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with re- fractory partial-onset seizures: A randomized, double-blind, pla- cebo-Controlled, parallel-group phase III study [ J ]. Epilepsia, 2009, 50 ( 3 ) :454 - 463.
  • 10MAIA J, ALMEIDA L, FALCAO A, et al. Effect of renal im- pairment on the harmacokinetics of eslicarbazepine acetate [ J ]. Int J Clin Pharmacol Ther, 2008, 46(3) :119 -130.

同被引文献74

  • 1郝学财,余晓斌,刘志钰,王蓓.响应面方法在优化微生物培养基中的应用[J].食品研究与开发,2006,27(1):38-41. 被引量:193
  • 2沈佳佳,张晓军,汪圣华,周晓云.微生物发酵法产环氧化物水解酶的研究[J].浙江工业大学学报,2006,34(2):131-136. 被引量:4
  • 3胡海峰,朱宝泉.微生物在药物开发中的应用[J].中国天然药物,2006,4(3):168-171. 被引量:6
  • 4FDA approves Aptiom to treat seizures in adults [ EB/OL]. [2013 -11- 08 ]. http : //www. fda. Gov/news events/newsroom/pressannouncements/ucm374358. htm.
  • 5Higgins JPT, Green S. Cochrane handbook for systematic reviews ofinterventions [ M]. Chichester: Wiley - Blackwell, 2008.
  • 6Ben - Menachem E,Gabbai AA,Hufnagel A,et al.Eslicarbazepine acetate as adjunctive therapy in adult patients withpartial epilepsy [ J ]. Epilepsy Res, 2010, 89 ( 2/3 ) , 278-285.
  • 7Eiger C, Bialer M, Cramer JA, et al. Eslicarbazepine acetate: adouble - blind, add - on, placebo - controlled exploratory trial inadult patients with partial - onset seizures [ J]. Epilepsia,2007,48(3): 497-504.
  • 8Eiger C,Haldsz P, Maia J, et al. Efficacy and safety ofeslicarbazepine acetate as adjunctive treatment in adults with refractorypartial - onset seizures : a randomized,double - blind,placebo -controlled, parallel - group phase III study [ J]. Epilepsia,2009,50 (3) : 454-463.
  • 9Gil - Nagel A, Lopes - Lima J, Almeida L, et al. Efficacy andsafety of 800 and 1 200 mg eslicarbazepine acetate as adjunctivetreatment in adults with refractory partial - onset seizures [ J ]. ActaNeurol Scand, 2009, 120 (5) : 281 -287.
  • 10Sperling MR, Bassel AK, Jay H, et al. Eslicarbazepine acetate asadjunctive therapy in patients with uncontrolled partial - onset seizures :results of a phase III, double - blind, randomized} placebo -controlled trial. [J]. Epilepsia, 2014, 56 (2): 244-253.

引证文献11

二级引证文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部